BMI1 is associated with CS8F amyloid-β and rates of cognitive decline in Alzheimer’s disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-9193
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
BMI1 is associated with CS8F amyloid-β and rates of cognitive decline in Alzheimer’s disease ; volume:13 ; number:1 ; day:5 ; month:10 ; year:2021 ; pages:1-8 ; date:12.2021
Alzheimer's research & therapy ; 13, Heft 1 (5.10.2021), 1-8, 12.2021
- Urheber
-
Kim, Jun Pyo
Kim, Bo-Hyun
Bice, Paula J.
Seo, Sang Won
Bennett, David A.
Saykin, Andrew J.
Nho, Kwangsik
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13195-021-00906-4
- URN
-
urn:nbn:de:101:1-2021122220100240610003
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 05:37 UTC
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kim, Jun Pyo
- Kim, Bo-Hyun
- Bice, Paula J.
- Seo, Sang Won
- Bennett, David A.
- Saykin, Andrew J.
- Nho, Kwangsik
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction to: BMI1 is associated with CSF amyloid-β and rates of cognitive decline in Alzheimer’s disease
Plaque complement activation and cognitive loss in Alzheimer's disease
Single-nucleus RNA velocity reveals critical synaptic and cell-cycle dysregulations in neuropathologically confirmed Alzheimer’s disease
Genome-wide epistasis analysis for Alzheimer’s disease and implications for genetic risk prediction
miR-129-5p as a biomarker for pathology and cognitive decline in Alzheimer’s disease
Protein farnesylation is upregulated in Alzheimer’s human brains and neuron-specific suppression of farnesyltransferase mitigates pathogenic processes in Alzheimer’s model mice
Specific serum antibody binding to phosphorylated and non-phosphorylated tau in non-cognitively impaired, mildly cognitively impaired, and Alzheimer’s disease subjects: an exploratory study
Epistatic effects of IGHG and FCGRIIB genes on the development of Alzheimer’s disease in African Americans
TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer’s disease
Mitigation of synaptic and memory impairments via F-actin stabilization in Alzheimer’s disease
Effects of brain microRNAs in cognitive trajectory and Alzheimer’s disease
Pathologic and clinical correlates of region-specific brain GFAP in Alzheimer’s disease
Correction to: BMI1 is associated with CSF amyloid-β and rates of cognitive decline in Alzheimer’s disease
Plaque complement activation and cognitive loss in Alzheimer's disease
Single-nucleus RNA velocity reveals critical synaptic and cell-cycle dysregulations in neuropathologically confirmed Alzheimer’s disease
Genome-wide epistasis analysis for Alzheimer’s disease and implications for genetic risk prediction
miR-129-5p as a biomarker for pathology and cognitive decline in Alzheimer’s disease
Protein farnesylation is upregulated in Alzheimer’s human brains and neuron-specific suppression of farnesyltransferase mitigates pathogenic processes in Alzheimer’s model mice
Specific serum antibody binding to phosphorylated and non-phosphorylated tau in non-cognitively impaired, mildly cognitively impaired, and Alzheimer’s disease subjects: an exploratory study
Epistatic effects of IGHG and FCGRIIB genes on the development of Alzheimer’s disease in African Americans
TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer’s disease
Mitigation of synaptic and memory impairments via F-actin stabilization in Alzheimer’s disease
Effects of brain microRNAs in cognitive trajectory and Alzheimer’s disease
Pathologic and clinical correlates of region-specific brain GFAP in Alzheimer’s disease
Correction to: BMI1 is associated with CSF amyloid-β and rates of cognitive decline in Alzheimer’s disease
Plaque complement activation and cognitive loss in Alzheimer's disease
Single-nucleus RNA velocity reveals critical synaptic and cell-cycle dysregulations in neuropathologically confirmed Alzheimer’s disease
Genome-wide epistasis analysis for Alzheimer’s disease and implications for genetic risk prediction
miR-129-5p as a biomarker for pathology and cognitive decline in Alzheimer’s disease
Protein farnesylation is upregulated in Alzheimer’s human brains and neuron-specific suppression of farnesyltransferase mitigates pathogenic processes in Alzheimer’s model mice
Specific serum antibody binding to phosphorylated and non-phosphorylated tau in non-cognitively impaired, mildly cognitively impaired, and Alzheimer’s disease subjects: an exploratory study
Epistatic effects of IGHG and FCGRIIB genes on the development of Alzheimer’s disease in African Americans
TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer’s disease
Mitigation of synaptic and memory impairments via F-actin stabilization in Alzheimer’s disease
Effects of brain microRNAs in cognitive trajectory and Alzheimer’s disease